Ifetroban

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ifetroban
Accession Number
DB12321
Type
Small Molecule
Groups
Investigational
Description

Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
BMS-180291
Product Ingredients
IngredientUNIICASInChI Key
Ifetroban Sodium48IJA0E92C156715-37-6WOHSQDNIXPEQAE-QBKVZTCDSA-M
Categories
UNII
E833KT807K
CAS number
143443-90-7
Weight
Average: 440.54
Monoisotopic: 440.231122138
Chemical Formula
C25H32N2O5
InChI Key
BBPRUNPUJIUXSE-DXKRWKNPSA-N
InChI
InChI=1S/C25H32N2O5/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29)/t18-,20-,21+,23-/m0/s1
IUPAC Name
3-(2-{[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl}phenyl)propanoic acid
SMILES
CCCCCNC(=O)C1=COC(=N1)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1CC1=CC=CC=C1CCC(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabIfetroban may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolIfetroban may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ifetroban is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Ifetroban is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the antiplatelet activities of Ifetroban.Approved, Investigational
AlteplaseIfetroban may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Ifetroban is combined with Aminosalicylic Acid.Approved
AnagrelideIfetroban may increase the anticoagulant activities of Anagrelide.Approved
AncrodIfetroban may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Ifetroban.Investigational
AnistreplaseIfetroban may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanIfetroban may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Apixaban.Approved
ArdeparinIfetroban may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanIfetroban may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinIfetroban may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the antiplatelet activities of Ifetroban.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Ifetroban is combined with Balsalazide.Approved, Investigational
BatroxobinIfetroban may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminIfetroban may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinIfetroban may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostIfetroban may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinIfetroban may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseIfetroban may increase the anticoagulant activities of Brinase.Experimental
BuflomedilIfetroban may increase the antiplatelet activities of Buflomedil.Experimental
ButylphthalideIfetroban may increase the antiplatelet activities of Butylphthalide.Investigational
CangrelorIfetroban may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabIfetroban may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Ifetroban is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinIfetroban may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolIfetroban may increase the anticoagulant activities of Cilostazol.Approved, Investigational
Citric AcidIfetroban may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelIfetroban may increase the anticoagulant activities of Clopidogrel.Approved
CloricromenIfetroban may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneIfetroban may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Ifetroban is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateIfetroban may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinIfetroban may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIfetroban may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIfetroban may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Ifetroban.Approved, Investigational
DefibrotideIfetroban may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ifetroban is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Ifetroban is combined with Dersalazine.Investigational
DesirudinIfetroban may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseIfetroban may increase the anticoagulant activities of Desmoteplase.Investigational
DextranIfetroban may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolIfetroban may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Ifetroban is combined with Diflunisal.Approved, Investigational
DiphenadioneIfetroban may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleIfetroban may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleIfetroban may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaIfetroban may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidIfetroban may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanIfetroban may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinIfetroban may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Ifetroban.Approved, Investigational
EplivanserinIfetroban may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineIfetroban may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolIfetroban may increase the anticoagulant activities of Epoprostenol.Approved
EptifibatideIfetroban may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateIfetroban may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidIfetroban may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinIfetroban may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneIfetroban may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxIfetroban may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateIfetroban may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Ifetroban.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Ifetroban is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Ifetroban is combined with Hemoglobin crosfumaril.Experimental
HeparinIfetroban may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineIfetroban may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolIfetroban may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ifetroban.Approved
IbudilastIbudilast may increase the antiplatelet activities of Ifetroban.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Ifetroban.Approved, Investigational, Nutraceutical
IdraparinuxIfetroban may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the antiplatelet activities of Ifetroban.Approved, Investigational, Withdrawn
IloprostIfetroban may increase the anticoagulant activities of Iloprost.Approved, Investigational
IndobufenIfetroban may increase the anticoagulant activities of Indobufen.Investigational
KetanserinIfetroban may increase the antiplatelet activities of Ketanserin.Investigational
LepirudinIfetroban may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanIfetroban may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostLimaprost may increase the antiplatelet activities of Ifetroban.Approved, Investigational
LinsidomineIfetroban may increase the antiplatelet activities of Linsidomine.Experimental
MelagatranIfetroban may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Ifetroban is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Ifetroban is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the antiplatelet activities of Ifetroban.Approved
NadroparinIfetroban may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatIfetroban may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the antiplatelet activities of Ifetroban.Investigational
NimesulideNimesulide may increase the antiplatelet activities of Ifetroban.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Ifetroban is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Ifetroban is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Ifetroban is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ifetroban.Approved, Nutraceutical
OtamixabanIfetroban may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelIfetroban may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinIfetroban may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateIfetroban may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ifetroban.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Ifetroban.Approved, Investigational
PhenindioneIfetroban may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonIfetroban may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Ifetroban is combined with Phenyl aminosalicylate.Approved
PicotamideIfetroban may increase the anticoagulant activities of Picotamide.Experimental
Potassium CitrateIfetroban may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasugrelIfetroban may increase the anticoagulant activities of Prasugrel.Approved
Protein CIfetroban may increase the anticoagulant activities of Protein C.Approved
Protein S humanIfetroban may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIfetroban may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanIfetroban may increase the antiplatelet activities of Ramatroban.Investigational
RelcovaptanIfetroban may increase the antiplatelet activities of Relcovaptan.Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Ifetroban.Approved, Experimental, Investigational
ReteplaseIfetroban may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinIfetroban may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Ifetroban.Approved
RivaroxabanIfetroban may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneIfetroban may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Ifetroban is combined with Salicylic acid.Approved, Investigational, Vet Approved
SarpogrelateIfetroban may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseIfetroban may increase the anticoagulant activities of Saruplase.Experimental
SelexipagIfetroban may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Ifetroban.Approved, Vet Approved
Sodium CitrateIfetroban may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SRT501SRT501 may increase the antiplatelet activities of Ifetroban.Investigational
StreptokinaseIfetroban may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideIfetroban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseIfetroban may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the antiplatelet activities of Ifetroban.Investigational
TicagrelorIfetroban may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineIfetroban may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinIfetroban may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolIfetroban may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Ifetroban.Approved, Investigational
TirofibanIfetroban may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ifetroban is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the antiplatelet activities of Ifetroban.Approved, Investigational
TrapidilTrapidil may increase the antiplatelet activities of Ifetroban.Approved
TreprostinilIfetroban may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalIfetroban may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Ifetroban is combined with Trolamine salicylate.Approved
TroxerutinIfetroban may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseIfetroban may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Ifetroban.Approved, Nutraceutical, Vet Approved
VorapaxarIfetroban may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinIfetroban may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIfetroban may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
3037233
PubChem Substance
347828584
ChemSpider
16736637
ChEMBL
CHEMBL3301673
Wikipedia
Ifetroban

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentLiver Cirrhosis / Portal Hypertension1
2CompletedTreatmentAspirin Exacerbated Respiratory Disease (AERD)1
2CompletedTreatmentHepatorenal Syndrome1
2Not Yet RecruitingTreatmentAspirin-exacerbated Respiratory Disease / Aspirin-sensitive Asthma With Nasal Polyps / Asthma, Aspirin-Induced / Polyps, Nasal1
2Not Yet RecruitingTreatmentDuchenne Muscular Dystrophy Cardiomyopathy / Duchenne's Muscular Dystrophy (DMD) / Muscular Diseases / Muscular Dystrophy / Muscular Dystrophy, Duchenne1
2RecruitingTreatmentAsthma, Aspirin-Induced1
2RecruitingTreatmentAutoimmune Diseases / Connective Tissue Diseases / Diffuse Systemic Sclerosis / Pathologic Processes / Scleroderma, Limited / Scleroderma, Systemic / Sclerosis, Progressive Systemic / Skin Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0146 mg/mLALOGPS
logP4ALOGPS
logP3.95ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)4.65ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.66 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity119.24 m3·mol-1ChemAxon
Polarizability48.95 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
2-heteroaryl carboxamides / 2,4-disubstituted oxazoles / Benzene and substituted derivatives / Oxolanes / Heteroaromatic compounds / Secondary carboxylic acid amides / Oxacyclic compounds / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids
show 5 more
Substituents
3-phenylpropanoic-acid / 2-heteroaryl carboxamide / 2,4-disubstituted 1,3-oxazole / Monocyclic benzene moiety / Benzenoid / Azole / Heteroaromatic compound / Oxazole / Oxolane / Carboxamide group
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:57 / Updated on August 02, 2018 06:37